The European Medicines Agency (EMA) has published the agenda for its Pharmacovigilance Risk Assessment Committee (PRAC) meeting scheduled for 8-11 June 2026. The committee will review ongoing safety signals, assess post-authorisation studies, and discuss risk management plans for several medicinal products.
The PRAC meeting, held quarterly, is the EMA's main body for monitoring and evaluating the safety of human medicines. The agenda includes evaluations of safety signals for drugs such as [specific drug names if available], as well as updates on periodic safety update reports (PSURs) and referrals. The committee will also consider requests for changes to product information based on new safety data.
Stakeholders impacted include pharmaceutical companies, which may face new labelling requirements or additional studies; healthcare professionals, who will receive updated safety guidance; and patients, who could see changes in risk-benefit assessments for certain treatments. The PRAC's recommendations are non-binding but typically adopted by the EMA's Committee for Medicinal Products for Human Use (CHMP) and the European Commission.
No prior coverage of this specific meeting exists in recent records. The meeting outcomes are expected to be published in the PRAC meeting minutes following the session.